Assessment of the Electronic Retinal Implant Alpha AMS in Restoring Vision to Blind Patients with End-Stage Retinitis Pigmentosa.

ABSTRACT:

Purpose

To report the initial efficacy results of the Retina Implant Alpha AMS (Retina Implant AG, Reutlingen, Germany) for partial restoration of vision in end-stage retinitis pigmentosa (RP).

Design

Prospective, single-arm, investigator-sponsored interventional clinical trial. Within-participant control comprising residual vision with the retinal implant switched ON versus OFF in the implanted eye.

Participants

The Retina Implant Alpha AMS was implanted into the worse-seeing eye of 6 participants with end-stage RP and no useful perception of light vision. Eligibility criteria included previous normal vision for ≥12 years and no significant ocular or systemic comorbidity.

Methods

Vision assessments were scheduled at 1, 2, 3, 6, 9, and 12 months postimplantatio

SUBMITTER: Edwards TL 

PROVIDER: S-EPMC5818267 | biostudies-literature | 2018 Mar

REPOSITORIES: biostudies-literature